Education
About Us
Working with TipRanks
Follow Us
Wave Life Sciences (WVE)
NASDAQ:WVE
WVE Analyst Ratings
Strong Buy
11 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
WVE Stock 12 Month Forecast
Average Price Target
$18.09
▲(78.23% Upside)
| Highest Price Target$24.00 | Average Price Target$18.09 | Lowest Price Target$9.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Canaccord Genuity
$19
Buy
87.19%
Upside
Reiterated
08/20/25
Positive Outlook for Wave Life Sciences: Promising Clinical Trials and Market Potential Drive Buy RatingWVE plans to report updated Ph1/2 WVE-006 data from the completed SAD and MAD 200mg cohorts this Q – we think sometime in the coming weeks (followed by 400mg SAD data "in the fall" per the co). As a reminder, SAD data from the first two patients dosed was shared in Oct 2024, showing an increase in both M-AAT (6.9µM) and total AAT (10.8µM). We're expecting positive data from the MAD cohort, given co commentary around greater liver exposure and higher liver concentration of WVE-006 with the multidose. We like the risk/reward in this update and expect ~30%+ upside on good news (for reference, shares were up ~74% from ~$9 to ~$15 on the Oct 2024 update) vs. transient ~10% downside on a disappointing update. Downside protection comes from more AATD data expected in the fall as noted above, as well as data from the (wholly owned, higher the obesity program coming later in the year.
Mizuho Securities
$22
Buy
116.75%
Upside
Reiterated
08/04/25
Truist Financial
―
Buy
―
Reiterated
07/31/25
H.C. Wainwright
$22
Buy
116.75%
Upside
Reiterated
07/31/25
Wells Fargo
$24→$21
Buy
106.90%
Upside
Reiterated
07/31/25
Oppenheimer
$24
Buy
136.45%
Upside
Initiated
07/31/25
Leerink Partners
$24
Buy
136.45%
Upside
Reiterated
07/30/25
Wave Life Sciences Poised for Growth: Buy Rating Affirmed Amid Upcoming CatalystsWe think these updates will be very important for WVE, which will begin with 200 mg multi-dose data for WVE-006 in 3Q25, then 400 mg single dose data in Fall 2025, and culminate with WVE-007 data for Cohorts 1 and 2 in 4Q25 and Cohort 3 in 1Q26. The stock's performance has been fairly lackluster in 1H25, which we think has been driven by a perceived lack of catalysts as WVE has been executing on these programs. As such, we encourage investors who have been on the sidelines to tune back in and re-engage with WVE ahead of these readouts. We continue to like WVE as one of our top picks this year based on our view that these data could provide multiple opportunities for significant appreciation in 2H25 and beyond. We are updating our model for quarterly results, leaving our $24 PT unchanged. Reiterate Outperform.
RBC Capital
$9
Hold
-11.33%
Downside
Reiterated
07/30/25
Wedbush
$18
Buy
77.34%
Upside
Reiterated
07/30/25
Citi
$16
Buy
57.64%
Upside
Initiated
07/17/25
Cantor Fitzgerald
$10
Buy
-1.48%
Downside
Reiterated
07/11/25
Raymond James
$14
Buy
37.93%
Upside
Initiated
06/10/25
JonesTrading
$20
Buy
97.04%
Upside
Reiterated
05/16/25
We are at ASGCT this week and caught Wave's oral sessions on their siRNA and RNA editing programs.
B.Riley Financial
$22→$19
Buy
87.19%
Upside
Reiterated
04/10/25
Jefferies
$26
Buy
156.16%
Upside
Reiterated
03/26/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Canaccord Genuity
$19
Buy
87.19%
Upside
Reiterated
08/20/25
Positive Outlook for Wave Life Sciences: Promising Clinical Trials and Market Potential Drive Buy RatingWVE plans to report updated Ph1/2 WVE-006 data from the completed SAD and MAD 200mg cohorts this Q – we think sometime in the coming weeks (followed by 400mg SAD data "in the fall" per the co). As a reminder, SAD data from the first two patients dosed was shared in Oct 2024, showing an increase in both M-AAT (6.9µM) and total AAT (10.8µM). We're expecting positive data from the MAD cohort, given co commentary around greater liver exposure and higher liver concentration of WVE-006 with the multidose. We like the risk/reward in this update and expect ~30%+ upside on good news (for reference, shares were up ~74% from ~$9 to ~$15 on the Oct 2024 update) vs. transient ~10% downside on a disappointing update. Downside protection comes from more AATD data expected in the fall as noted above, as well as data from the (wholly owned, higher the obesity program coming later in the year.
Mizuho Securities
$22
Buy
116.75%
Upside
Reiterated
08/04/25
Truist Financial
―
Buy
―
Reiterated
07/31/25
H.C. Wainwright
$22
Buy
116.75%
Upside
Reiterated
07/31/25
Wells Fargo
$24→$21
Buy
106.90%
Upside
Reiterated
07/31/25
Oppenheimer
$24
Buy
136.45%
Upside
Initiated
07/31/25
Leerink Partners
$24
Buy
136.45%
Upside
Reiterated
07/30/25
Wave Life Sciences Poised for Growth: Buy Rating Affirmed Amid Upcoming CatalystsWe think these updates will be very important for WVE, which will begin with 200 mg multi-dose data for WVE-006 in 3Q25, then 400 mg single dose data in Fall 2025, and culminate with WVE-007 data for Cohorts 1 and 2 in 4Q25 and Cohort 3 in 1Q26. The stock's performance has been fairly lackluster in 1H25, which we think has been driven by a perceived lack of catalysts as WVE has been executing on these programs. As such, we encourage investors who have been on the sidelines to tune back in and re-engage with WVE ahead of these readouts. We continue to like WVE as one of our top picks this year based on our view that these data could provide multiple opportunities for significant appreciation in 2H25 and beyond. We are updating our model for quarterly results, leaving our $24 PT unchanged. Reiterate Outperform.
RBC Capital
$9
Hold
-11.33%
Downside
Reiterated
07/30/25
Wedbush
$18
Buy
77.34%
Upside
Reiterated
07/30/25
Citi
$16
Buy
57.64%
Upside
Initiated
07/17/25
Cantor Fitzgerald
$10
Buy
-1.48%
Downside
Reiterated
07/11/25
Raymond James
$14
Buy
37.93%
Upside
Initiated
06/10/25
JonesTrading
$20
Buy
97.04%
Upside
Reiterated
05/16/25
We are at ASGCT this week and caught Wave's oral sessions on their siRNA and RNA editing programs.
B.Riley Financial
$22→$19
Buy
87.19%
Upside
Reiterated
04/10/25
Jefferies
$26
Buy
156.16%
Upside
Reiterated
03/26/25
Best Analysts Covering Wave Life Sciences
1 Month
xxx
Success Rate
8/15 ratings generated profit
Average Return
+7.27%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.33% of your transactions generating a profit, with an average return of +7.27% per trade.
3 Months
xxx
Success Rate
8/15 ratings generated profit
Average Return
+22.08%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 53.33% of your transactions generating a profit, with an average return of +22.08% per trade.
1 Year
Success Rate
12/15 ratings generated profit
Average Return
+35.65%
reiterated a buy rating 24 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +35.65% per trade.
2 Years
xxx
Success Rate
12/15 ratings generated profit
Average Return
+44.27%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +44.27% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
WVE Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
17
21
15
19
15
Buy
5
5
3
4
3
Hold
8
10
6
8
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
30
36
24
31
27
Each month's total comprises the sum of three months' worth of ratings.
WVE Financial Forecast
WVE Stock Forecast FAQ
What is WVE’s average 12-month price target, according to analysts?
Based on analyst ratings, Wave Life Sciences’s 12-month average price target is 18.09.
What is WVE’s upside potential, based on the analysts’ average price target?
Wave Life Sciences has 78.23% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is WVE a Buy, Sell or Hold?
Wave Life Sciences has a consensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.
What is Wave Life Sciences’s price target?
The average price target for Wave Life Sciences is 18.09. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $24.00 ,the lowest forecast is $9.00. The average price target represents 78.23% Increase from the current price of $10.15.
The highest analyst price target is $24.00 ,the lowest forecast is $9.00. The average price target represents 78.23% Increase from the current price of $10.15.
What do analysts say about Wave Life Sciences?
Wave Life Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of WVE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.